PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells

被引:43
作者
Baratelli, F
Krysan, K
Heuzé-Vourc'h, N
Zhu, L
Escuadro, B
Sharma, S
Reckamp, K
Dohadwala, M
Dubinett, SM
机构
[1] Univ Calif Los Angeles, Lung Canc Res Program, Div Pulm & Crit Care Med,Dept Med, Geffen Sch Med,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
[2] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA
关键词
lipid mediators; immune cells; antiapoptotic proteins;
D O I
10.1189/jlb.1004569
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Control of apoptosis is fundamental for dendritic cell (DC) homeostasis. Numerous factors maintain DC viability throughout their lifespan, including inhibitor of apoptosis proteins. Among them, survivin is overexpressed in many human malignancies, but its physiological function in normal cells has not been fully delineated. Prostaglandin E-2 (PGE(2)), also overproduced in several malignancies, has shown to induce proapoptotic and antiapoptotic effects in different cell types, including immune cells. In DC, PGE(2) predominantly affects maturation and modulates immune functions. Here, we show that exposure of monocyte-derived DC to PGE(2) (10(-5) M) for 72 h significantly increased DC survivin mRNA and protein expression. In contrast, DC, matured with lipopolysaccharide or tumor necrosis factor alpha, did not reveal survivin induction in response to PGE(2). Following exposure to apoptotic stimuli, DC treated with PGE(2) exhibited an overall increased viability compared with control DC, and this effect was correlated inversely with caspase-3 activation. Moreover, PGE(2)-treated, survivin-deficient DC demonstrated reduced viability in response to apoptotic stimuli. Further analysis indicated that PGE(2) induced DC survivin expression in an E prostanoid (EP)(2)/EP4 receptor and phosphatidylinositol-3 kinase-dependent manner. These findings suggest that PGE(2)-dependent regulation of survivin is important in modulating apoptosis resistance in human DC.
引用
收藏
页码:555 / 564
页数:10
相关论文
共 56 条
[1]   Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].
Altorki, NK ;
Keresztes, RS ;
Port, JL ;
Libby, MD ;
Korst, RJ ;
Flieder, DB ;
Ferrara, CA ;
Yankelevitz, DF ;
Subbaramaiah, K ;
Pasmantier, MW ;
Dannenberg, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650
[2]   Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils [J].
Altznauer, F ;
Martinelli, S ;
Yousefi, S ;
Thürig, C ;
Schmid, I ;
Conway, EM ;
Schöni, MH ;
Vogt, P ;
Mueller, C ;
Fey, MF ;
Zangemeister-Wittke, U ;
Simon, HU .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (10) :1343-1354
[3]   The PI3 kinase, p38 SAP kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells [J].
Ardeshna, KM ;
Pizzey, AR ;
Devereaux, S ;
Khwaja, A .
BLOOD, 2000, 96 (03) :1039-1046
[4]  
Ashany D, 1999, J IMMUNOL, V163, P5303
[5]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[6]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[7]   Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix [J].
Baratelli, FE ;
Heuzé-Vourc'h, N ;
Krysan, K ;
Dohadwala, M ;
Riedl, K ;
Sharma, S ;
Dubinett, SM .
JOURNAL OF IMMUNOLOGY, 2004, 173 (09) :5458-5466
[8]   Inhibitor of apoptosis protein survivin regulates vascular injury [J].
Blanc-Brude, OP ;
Yu, J ;
Simosa, H ;
Conte, MS ;
Sessa, WC ;
Altieri, DC .
NATURE MEDICINE, 2002, 8 (09) :987-994
[9]   Prostanoid receptors: Subtypes and signaling [J].
Breyer, RM ;
Bagdassarian, CK ;
Myers, SA ;
Breyer, MD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :661-690
[10]  
Brown DM, 1996, J IMMUNOL, V157, P1359